Étude d'un locus pour trait quantitatif de l'hypertension sur le chromosome 3 du rat Dahl Salt-Sensitive

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Localisation d'un locus pour trait quantitatif pour l'hypertension sur le chromosome 18 du rat Dahl

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Identification of blood pressure genes in the Dahl salt-sensitive hypertension model

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Localisation d'un locus pour trait quantitif pour l'hypertension sur le chromosome 2 du rat Dahl

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Mécanismes impliqués dans le développement du remodelage eutrophique des artères de résistance et du coeur dans un modèle d'hypertension induite par l'inhibition de la synthèse du NO

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Régression de la calcification artérielle médiale comme avenue thérapeutique potentielle pour l'hypertension systolique isolée

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Rôle du stress oxydatif dans l'augmentation de l'expression des protéines Gi[alpha] dans l'hypertension

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

La production de l'anion superoxyde par l'angiotensine, l'endothéline et les voies de signalisation dépendantes de l'acide arachidonique dans les tissus vasculaires dans le développement de l'hypertension

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis

BACKGROUND: The development of heart failure is associated with changes in the size, shape, and structure of the heart that has a negative impact on cardiac function. These pathological changes involve excessive extracellular matrix deposition within the myocardial interstitium and myocyte hypertrophy. Alterations in fibroblast phenotype and myocyte activity are associated with reprogramming of gene transcriptional profiles that likely requires epigenetic alterations in chromatin structure. The aim of our work was to investigate the potential of a currently licensed anticancer epigenetic modifier as a treatment option for cardiac diseases associated with hypertension-induced cardiac hypertrophy and fibrosis.

METHODS AND RESULTS: The effects of DNA methylation inhibition with 5-azacytidine (5-aza) were examined in a human primary fibroblast cell line and in a spontaneously hypertensive rat (SHR) model. The results from this work allude to novel in vivo antifibrotic and antihypertrophic actions of 5-aza. Administration of the DNA methylation inhibitor significantly improved several echocardiographic parameters associated with hypertrophy and diastolic dysfunction. Myocardial collagen levels and myocyte size were reduced in 5-aza-treated SHRs. These findings are supported by beneficial in vitro effects in cardiac fibroblasts. Collagen I, collagen III, and α-smooth muscle actin were reduced in a human ventricular cardiac fibroblast cell line treated with 5-aza.

CONCLUSION: These findings suggest a role for epigenetic modifications in contributing to the profibrotic and hypertrophic changes evident during disease progression. Therapeutic intervention with 5-aza demonstrated favorable effects highlighting the potential use of this epigenetic modifier as a treatment option for cardiac pathologies associated with hypertrophy and fibrosis.

AN ECONOMIC ANALYSIS OF THE ADDITION OF BEVACIZUMAB TO STANDARD CHEMOTHERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

Thesis (Master's)--University of Washington, 2016-08

Gender mismatch between donor and recipient is a factor of morbidity but does not condition survival after cardiac transplantation

We intended to evaluate the influence of sex mismatch between donor and recipient, which is still under much debate, on survival and comorbidities after cardiac transplantation. From November 2003 to December 2013, a total of 258 patients were transplanted in our center. From these, 200 receptors were male (77.5%) and constituted our study population, further divided into those who received the heart from a female donor (Group A) - 44 patients (22%) and those who received it from a male donor (Group B) - 156 (78%). Median follow-up was 4.2 ± 3.0 years (1-10 years). The two groups were quite comparable with each other, except for body mass index, systolic pulmonary artery pressure, and transpulmonary gradient, which were significantly lower in Group A. A low donor/recipient weigh ratio (<0.8) was avoided whenever possible. Hospital mortality was not different in the two groups. During follow-up, global survival was similar, as was survival free from acute cellular rejection and cardiac allograft vasculopathy. However, patients in Group A had decreased survival free from serious infections and malignant tumors. Allocation of female donors to male receptors can be done safely, at least in receptors without pulmonary hypertension and when an adequate donor/recipient weigh ratio is ensured.